Bookmark this page or recommend it.

The IOP Thyroid Carcinoma coordinates the interdisciplinary treatment of patients with thyroid cancer.

Participating medical facilities and centres of excellence include:

• Department of Visceral Surgery (thyroid surgery with grade-adapted lymphadenectomy, metastatic surgery).
• Department of Nuclear Medicine (pre-operative diagnostic, radiotherapy, FDG, PET, after care).
• Department II of Internal Medicine (after care, therapy by hypoparatyroidism).
• Department II of Internal Medicine II (chemotherapy, targeted drug therapy).
• Department of ENT (neck lymph node resection, after care by recurrent pareses).
• Department of Radiation Therapy (irradiation by loco-regional recurrence and distant metastasis).
• Institute for Radiological Diagnostic (entire diagnostic spectrum), and
• Institute of Pathology (cytology, rapid section, histology, reference pathology.  

The applied Standard Operating Procedure (SOP), which is based on the German Cancer Society guidelines, is the foundation for the treatment provided by CIO Köln and Bonn and guarantees our patients quality based care at the highest level. Patient care services are provided through individual clinical consultation sessions by participating clinics. Furthermore, during meetings of the Tumour Boards in Köln and Bonn, complex clinical findings are jointly discussed.  

Radioiodine therapy and diagnostics

Radioiodine therapy and radioiodine diagnostic require significant thyroid stimulating hormone (TSH) treatment, which until now, was only achievable through TSH withdrawal over several weeks. After the surgical removal of the thyroid gland, this resulted in a severe under-function of the thyroid. Nowadays, this hypothyroidism can be avoided by giving the patient twice an injection of recombinant human TSH (rhTSH - Thyrogen®).  RhTSH  is registered for radioiodine therapy in the ablation of residual thyroid tissue, usage as a radioiodine diagnostic agent, as well as for estimating  thyreoglobulin under TSH stimulation. Both injections of rhTSH are given in the Clinic for Nuclear Medicine Köln or the Clinic for Nuclear Medicine Bonn prior to the administration of radioactive iodine (I-131) and before admission to the ward. 

Thyreoglobulin (Tg) Measurement

The measurement of thyreoglobulin under rhTSH is a very sensitive laboratory marker in the after care of the differentiated thyroid carcinoma.  The after care is being simplified through the estimation of thyreoglobulin under thyroid hormone medication or rhTSH in an outpatient setting. This procedure saves many patients from re-admission and negates additional diagnostic imaging and the associated exposure to radiation. Both rhTSH injections are given to patients in the outpatient departments of the Clinic for Nuclear Medicine Köln and the Clinic for Nuclear Medicine Bonn respectively.

If you want to be treated at the CIO Bonn, more information regarding consultation hours is available under: Appointments for consultation for thyroid carcinoma

Personal Profile:

Professor Markus Dietlein

Research Focus

Professor Dietlein is the leading author on methods and procedures published by the German Society for Nuclear Medicine (DGN). He was also closely involved in the preparation of the national S3 clinical guideline for the management of thyroid cancer and coordinated the Thyroid Section of the German Endocrinological Society (DGE). Professor Dietlein is the author of a review published by Thieme Refresher Oncology (http://cme.thieme.de).

Other research priorities include:

• Therapeutic monitoring using PET by Hodgkin Lymphoma ((HD15, HD18 of the German Hodgkin Study Group), lung cancer and oesophageal carcinoma.
• Integration of radio-immune therapy by malignant lymphoma in a interdisciplinary treatment concept.
• Numerous publications in the German biomedical journal Nuklearmedizin.

> Back